Ex Vivo Venetoclax Sensitivity Predicts Clinical Response in Acute Myeloid Leukemia in the Prospective VenEx Trial.

Autor: Kytölä S; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland., Vänttinen IM; University of Helsinki, Helsinki, Finland., Ruokoranta T; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Partanen A; Kuopio University Hospital, Kuopio, Finland., Holopainen A; Kuopio University Hospital, Kuopio, Finland., Saad J; University of Helsinki, Helsinki, Finland., Kuusisto MEL; University of Oulu and Oulu University Hospital, Oulu, Finland, Oulu, Finland., Koskela S; Finland., Räty RK; HUS Helsinki University Central Hospital, Helsinki, Finland., Itälä-Remes M; Turku University Hospital, Turku, Finland., Västrik I; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Suvela M; University of Helsinki, Helsinki, Finland., Parsons AO; University of Helsinki, Helsinki, Finland., Porkka K; Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland., Wennerberg K; University of Copenhagen, Copenhagen N, Denmark., Heckman CA; University of Helsinki, Helsinki, Finland., Jalkanen T; Estimates Ltd, Turku, Finland., Huttunen T; Estimates Ltd, Turku, Finland., Ettala P MD; Turku University Hospital, Turku, Finland., Rimpiläinen J; Tampere University Hospital, Tampere, Finland., Siitonen T; Oulu University Hospital, Oulu, Finland., Pyörälä M; Kuopio University Hospital, Kuopio, Finland., Kuusanmäki H; Institute of Molecular Medicine Finland (FIMM), Helsinki, Finland., Kontro M; Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

Publikováno v: Blood [Blood] 2024 Oct 02. Date of Electronic Publication: 2024 Oct 02.